These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 27678023)

  • 1. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
    Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
    Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
    Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
    Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
    Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
    Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
    Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway.
    Tao S; Chen Y; Hu M; Xu L; Fu CB; Hao XB
    Mol Cell Biochem; 2022 Mar; 477(3):951-963. PubMed ID: 35098439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.
    Walker MP; Stopford CM; Cederlund M; Fang F; Jahn C; Rabinowitz AD; Goldfarb D; Graham DM; Yan F; Deal AM; Fedoriw Y; Richards KL; Davis IJ; Weidinger G; Damania B; Major MB
    Sci Signal; 2015 Feb; 8(362):ra12. PubMed ID: 25650440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
    Goatly A; Bacon CM; Nakamura S; Ye H; Kim I; Brown PJ; Ruskoné-Fourmestraux A; Cervera P; Streubel B; Banham AH; Du MQ
    Mod Pathol; 2008 Jul; 21(7):902-11. PubMed ID: 18487996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 18. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.
    Wlodarska I; Veyt E; De Paepe P; Vandenberghe P; Nooijen P; Theate I; Michaux L; Sagaert X; Marynen P; Hagemeijer A; De Wolf-Peeters C
    Leukemia; 2005 Aug; 19(8):1299-305. PubMed ID: 15944719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
    Hu CR; Wang JH; Wang R; Sun Q; Chen LB
    Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.